ClinicalTrials.gg
Status unknownNCT03245333Updated Dec 12, 2017

A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA)

A Phase 3 interventional study of Recombinant Human Growth Hormone Injection and Recombinant Human Growth Hormone Injection in Small for Gestational Age Infant, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 24 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Dec 2014, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
24 Years to 90 Years
Sex
All
01

Study summary

According to the results of the phase II study, choose the best dose of JINTOPIN AQ for short SGA children, further to evaluate the efficacy and safety of the treatment of short SGA children.

02

Conditions studied

  • Small for Gestational Age Infant
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of full-term small for gestational age, SGA.
  • Chronological age between 2-6.5 years in girls and 2-7.5 years in boys. Both genders.
  • Prepubertal stage (Tanner I).
  • Height was lower than the mean -2SD of the values of normal children of the same age and gender when participating in the study.
  • A GH peak concentration >10µg/L in a provocative test within a year before participating in the study.
  • Bone age\<Chronological age+1.
  • Normal glucose regulation:Fasting blood-glucose \< 5.6mmol/L, and 2 hours postprandial blood-glucose \< 7.8mmol/L.
  • Gestational age was 37 to 42 weeks.
  • The subjects and their guardians signed .

Exclusion criteria

Exclusion Criteria:

  • Subjects with Liver and renal insufficiency ( > 1.5 times of value, Cr> upper limit of normal value).
  • Patients are positive for antibodies to core (HBc), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg).
  • Known Highly allergic constitution or allergic to the test drug.
  • Subjects with diabetes, severe cardiopulmonary and pulmonary disease, and hematological diseases, malignant tumors, or systemic infection, patients and patients with psychosis.
  • Subjects with other growth disorders, such as Turner syndrome, constitutional delay of growth and puberty, and Laron syndrome and growth hormone receptor deficiency.
  • Subjects who have received the treatment of GH.
  • Subjects took part in other clinical trial study within 3 months.
  • Children who have treated with other hormone (such as gonadal hormone and etc, continuous administration of more than a month) and that may affect growth hormone secretion or action including oxygen male dragon, growth hormone releasing hormone, etc. within 3 months.
  • Other conditions which in the opinion of the investigator preclude enrollment into the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Stage 1-experimental group

    JINTOPIN AQ 0.2IU/kg/d(0.46mg/kg /wk), for 52 weeks.

    Drug: Recombinant Human Growth Hormone Injection

  • Other
    Stage 1-negative control

    observed only for 52 weeks.

    Drug: Recombinant Human Growth Hormone Injection

  • Experimental
    Stage 2-experimental group

    After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.

    Drug: Recombinant Human Growth Hormone Injection

  • Other
    Stage 2-negative control

    After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.

    Drug: Recombinant Human Growth Hormone Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change of height standard deviation score for chronological age (△Ht SDSCA)

    △Ht SDS= Ht SDSafter treatment - Ht SDSbaseline Ht SDSCA = (height - reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint )

    Time frame: 52 weeks

Secondary outcomes

  1. Height(Ht)at the end of treatment

    Time frame: Stage 1:52 weeks

  2. Height(Ht)at the end of treatment

    Time frame: Stage 2:Every 52 weeks, up to 3 years

  3. Annualized height velocity (HV)

    Time frame: Stage 1:52 weeks

  4. Annualized height velocity (HV)

    Time frame: Stage 2:Every 52 weeks, up to 3 years

  5. Bone age maturation

    Time frame: Stage 1:52 weeks

  6. Bone age maturation

    Time frame: Stage 2:Every 52 weeks, up to 3 years

  7. Mole ratio of IGF-1 and IGFBP-3

    Time frame: Stage 1:52 weeks

  8. Mole ratio of IGF-1 and IGFBP-3

    Time frame: Stage 2:Every 52 weeks, up to 3 years

  9. IGF-1 standard deviation score (SDS)

    Time frame: Stage 1:52 weeks

  10. IGF-1 standard deviation score (SDS)

    Time frame: Stage 2:Every 52 weeks, up to 3 years

07

Study locations

5 of 5 sites recruiting
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
  • The first affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
  • The Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • Beijing Children's Hospital, Capital Medical University
    Beijing, China
    Recruiting
  • Shanghai Children's Hospital
    Shanghai, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2014 (actual). Primary completion is estimated for Dec 2017, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2017
First posted
Aug 10, 2017
StartActual
Dec 2014
Primary completionEst.
Dec 2017
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03245333
Collaborators
Tongji Hospital, Beijing Children's Hospital, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Dec 2014
Primary completion
Dec 2017 (estimated)
Last update
Dec 12, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
0431-85170552
Xiaoping Luo
Contact
xpluo@tjh.tjmu.edu.cn
+86-27-83663712

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion